Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Patch Formulation May Provide New Option for Clinicians Concerned ... Systemic Exposure When ... Alpharma Inc. (NYSE: ALO ),a leading global ... presented this week at the American Pain Society annual,meeting ...
... Inc.,(Nasdaq: ARNA ) announced today that Taisho ... of a drug candidate under a GPCR-focused,partnership with ... drug candidate is a novel oral compound intended ... "We are very happy to see our long-standing ...
Cached Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:9/1/2014)... September 01, 2014 The B-cell non-Hodgkin’s ... across six major markets (the US, France, Italy, Germany, ... to $5.41 billion by 2018. , The competitive landscape ... Italy, Germany, Spain and the UK is poised to ... management of the four largest B-cell NHL indications, which ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... As well as having completed the ... pursuing counselor certification in Louisiana. , "I ... training program as well as the Counselor training ... personally and professionally. I am not only dedicated ... to do so. As a Non Violent Crisis ...
(Date:9/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , the global market for ... and is expected to reach $38.7 million in 2014. ... by 2019, which is equivalent to 64.9% compound annual ... transport (RMT) segment is forecasted to grow at a ...
(Date:9/1/2014)... Oakdale, MN (PRWEB) September 01, 2014 In honor ... place on Aug. 22, Animal Emergency & Referral Center of Minnesota ... veterinarian visits a priority for their cats. , Many people don’t ... “it’s too much of a hassle,” but they wouldn’t decide not ... no signs of a cavity. The same goes for pets. Just ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... GAITHERSBURG, Md., Dec. 5 Panacea Pharmaceuticals, ... a fully human sequence,monoclonal antibody against HAAH ... in collaboration with the Massachusetts Institute of ... efficacy in animal,models of cancer. Having a ...
... publication Head and Neck Pathology. Published under the Humana ... North American Society for Head and Neck Pathology (NASHNP). ... December 2007, it will be available free of charge for ... Pathology will present scholarly papers, reviews and case reports that ...
... new ways of tweaking the molecular structure of antibiotics ... fight against powerful super bugs. , The work, led ... geneticist Professor Colin Smith, is published online today (Wednesday ... of the Journal of the American Chemical Society. , ...
... Clinical study compares rotational stability of two differently designed, ... of every day viewing conditions, JACKSONVILLE, Fla., Dec. ... vision may sometimes fluctuate during the day, the answer,may ... new clinical study,demonstrates. The findings, say researchers, may be ...
... Inc., a,medical device company developing endovascular devices for ... announced,the appointment of Christopher R. Barys to the ... to FlowCardia with over 16 years of,experience in ... in the,interventional endovascular products field., Most recently, ...
... Alliance, the leading,management consulting firm specializing in the ... Vice President,of the firm,s Business Development practice, will ... at the Strategic Research,Institute,s (SRI) Pharma & Biotech ... on December 10-11, 2007, at the San Diego ...
Cached Medicine News:Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 2Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 3Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 4Health News:Scientists strike blow in superbugs struggle 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 3Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 4Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 5Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: